Jean A. van Wyk, MB,ChB; MFPM

Global Medical Lead, VP
ViiV Healthcare Limited
Brentford, England, United Kingdom

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):

• 1582 - Real-World Use of Long-Acting Cabotegravir + Rilpivirine in the US: Effectiveness in the First Year

  Friday, October 21, 2022
  3:15 PM – 3:30 PM US ET

• 1584 - CARISEL A Hybrid III Implementation Effectiveness Study of implementation of Cabotegravir plus Rilpivirine Long Acting (CAB+RPV LA) in EU Health Care Settings Key Clinical and Implementation Outcomes by Implementation Arm

  Friday, October 21, 2022
  3:45 PM – 4:00 PM US ET

• 1586 - Phase 3/3b Experience with Long-Acting Cabotegravir and Rilpivirine: Efficacy and Safety Outcomes Through Week 96 by Race

  Friday, October 21, 2022
  4:15 PM – 4:30 PM US ET

• 2255 - Suppressed Switch to DTG/3TC 2-Drug Regimen Vs. BIC- or DTG-Based 3-Drug Regimens

  Saturday, October 22, 2022
  12:15 PM – 12:45 PM US ET